Genfit FR0004163111

DSMB approves

1. Opstapelen 25 oktober 2013 18:09

   auteur info

   • Opstapelen

     Lid sinds: 23 okt 2005

     Laatste bezoek: 28 apr 2024

   • Aanbevelingen

     Ontvangen: 1398

     Gegeven: 434

   •    Aantal posts: 4.884

   Hoppa, riemen vast maandag, unrestricted approve!
   
   genfit.com/fileadmin/press/press/pres...
   
   The independent Data Safety Monitoring Board (DSMB) of international experts, after analyzing the safety data for GFT505 in the ongoing Phase IIb clinical trial, unanimously recommends continuing the study according to the planned protocol
   Lille (France), Boston (Massachusetts, United States), October 25, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the recommendation of the independent Data Safety and Monitoring Board (DSMB) of international experts charged with ensuring the safety of use of GFT505 in the current Phase IIb study. The DSMB gives its unrestricted approval to continue the Phase IIb clinical trial in NASH according to the planned protocol.
   GENFIT launched the Phase IIb study of GFT505 in NASH in September 2012, after obtaining FDA (Food and Drug Administration) approval to perform the study in the United States. To date the study has recruited 139 diabetic and non-diabetic patients with a histological diagnosis of NASH by liver biopsy at the time of recruitment. The study is currently ongoing in Europe and the United States in 56 clinical investigation centers.
   The members of the DSMB, an independent committee set up to ensure patient safety within the Phase IIb study, analyzed the complete safety data for patients that have been treated for more than 6 months with GFT505 at 80 mg/day.
   The members of the DSMB unanimously concluded that, after more than 6 months of treatment at the dose of 80 mg/day, GFT505 shows no safety issue that compromises the continuation of the Phase IIb study.
   Jean-François MOUNEY, Chairman and Chief Executive Officer of GENFIT, declared: « We are extremely pleased with this decision that marks a much-awaited key step in this study, and further adds to the potential value of our drug candidate. Indeed the DSMB has given its unrestricted approval to move to the higher dose of GFT505, and recommends the continuation of the study according to the planned protocol. Consequently, the next patients that are randomized to receive GFT505 in the trial will be treated at 120 mg/day for 12 months. »
2. Opstapelen 25 oktober 2013 20:32

   auteur info

   • Opstapelen

     Lid sinds: 23 okt 2005

     Laatste bezoek: 28 apr 2024

   • Aanbevelingen

     Ontvangen: 1398

     Gegeven: 434

   •    Aantal posts: 4.884

   Aansluitend de half jaar resultaten,
   
   genfit.com/fileadmin/press/press/pres...
   
   Maar alles staat in het teken van GFT505 nu, dit gaat heel groot worden dames en heren.
3. [verwijderd] 5 november 2015 15:32

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   What kind of drug are we talking about here? and what are the benefits of the same.